Historically, the biopharmaceutical industry has relied on traditional pharmaceutical manufacturing practices to make and release products. This publication examines the future of biopharmaceutical manufacturing by presenting the vision of fully implemented in-line monitoring (ILM) and real-time release. This aspirational vision includes full ILM, predictive analytics and advanced process controls (APC) enabling release of product in real time, with concomitant predictive and preventative alerts and resolution of process, equipment and other production issues.
ILM and RTR
Viewing related articles
Attribute matrix on PAT for in-line monitoring and real-time release
Oct 2021 | Benchmarking, FF ILM/RTR, Fill Finish
A BioPhorum member only attribute matrix consisting of analysis of the current and desired state of PAT for ILM/RTR
Continued Process Verification (CPV): A guide to integrating continued process verification (CPV) and annual product review (APR)
Jun 2021 | CPV, Deliverable, Drug Substance, POI - Drug Substance, Publication
This paper draws on the experiences of more than 20 biopharmaceutical manufacturing companies in creating CPV reports and integrating them with their APR processes to propose an approach that significantly improves efficiency while still complying with regulations and achieving the business benefits of a robust CPV program
Environmental monitoring (EM): Risk assessment template
Feb 2019 | COVID 19, Environmental Monitoring in Drug Product (EMinDP), Fill Finish, POI - Fill Finish
This Excel spreadsheet tool compliments the guidance document ‘Environmental monitoring: harmonized risk-based approach to selecting monitoring points and defining monitoring plans’. This allows the user to assess a room against six factors, the amenability of equipment and surfaces to cleaning and sanitization, personnel presence and flow, material flow, proximity to open product or exposed direct product contact material, the need for interventions/operations and their complexity, frequency of intervention and score them
Continued process verification (CPV) and the validation of informatics systems
Nov 2018 | Continued process verification, Drug Substance, Fill Finish, POI - Drug Substance
Continued process verification (CPV) provides ongoing verification of the performance of a manufacturing process and as such entails the processing of large amounts of data. This paper draws on the experiences of multiple biopharmaceutical manufacturing companies in validating the informatics components of their CPV programs. It sheds light on common issues and provides recommendations and best practices. Computer systems validation is relevant across the lifecycle of a CPV informatics solution. As such the papers scope includes the initial and ongoing activities and deliverables to determine that the solution meets its intended uses and other requirements, for example, data integrity and performance requirements.Â
Container closure (CCI): Dye ingress methods for container-closure integrity testing: An industry position paper
Sep 2018 | Fill Finish
The release of the expanded USP<1207> in 2016 cast doubt over the validity of so-called probabilistic analytical methods, including one the biopharmaceutical industry’s most universal tests – the dye ingress method for container closure integrity
With the dye ingress method ubiquitously used without issue for decades, this paper highlights the continued value and applicability of this and other probabilistic analytical tests. In addition, this paper also describes how any method, whether probabilistic or deterministic, stands or falls on the quality of its development and validation, and not necessarily on the properties of the test itself.
The most important factor is to apply a test method is not how it is labelled, but lies in its development, qualification and whether it meets the need for which it is designed.
Continued process verification (CPV) of legacy products in the biopharmaceutical industry
Jun 2018 | Continued process verification, CPV, Drug Substance, POI - Drug Substance, Publication
This guide to the implementation of continued process verification (CPV) across a portfolio of legacy products complements the foundational document ‘Continued process verification (CPV): An industry position paper with an example plan’ published in 2014. The guide helps biomanufacturers understand how to build efficient and effective plans for legacy products and links to QA systems, provides guidance on implementations across multiple sites and advises on discovery, disclosure and regulatory reporting.